X-linked inhibitor of apoptosis (XIAP) is the most potent human inhibitor of apoptosis, and is also involved in NOD2-dependent NFκB and MAPK signalling cascade activation. The absence or defective function of XIAP leads to the development of a rare and severe primary immunodeficiency known as X-linked lymphoproliferative syndrome type 2 (XLP-2), which is characterized by a triad of clinical manifestations, including a high incidence of haemophagocytic lymphohistiocytosis (HLH), lymphoproliferation and inflammatory bowel disease (IBD), usually with very early onset. Here, we present a novel XIAP mutation identified in a patient with atypical adult-onset IBD complicated by relapsing HLH, splenomegaly and sarcoid-like disease. The c.266delA mutation in the XIAP gene creates a premature stop codon, and causes a severe reduction in XIAP protein expression. The mutation is also associated with impaired spontaneous and staurosporine- and PMA-induced apoptosis accompanied by significantly increased expression of pro-apoptotic genes. We also confirmed the negative impact of this particular XIAP mutation on NOD2-dependent NFκB and MAPK activation, while NOD2-independent activation was found to be unaffected. Moreover, we assume that the mutation has an impact on the overproduction of IL-12 and IFNγ, the shift towards the Th1 immune response and increased numbers of central memory and effector memory CD4+ and CD8+ T cells. All these changes contribute to immune dysregulation and the clinical manifestation of XLP-2.

CLIP Childhood Leukaemia Investigation Prague Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine Charles University and University Hospital Motol Prague Czech Republic

Department of Immunology 2nd Faculty of Medicine Charles University University Hospital in Motol 5 Uvalu 84 Prague Czech Republic

Faculty of Medicine Masaryk University Brno Czech Republic

Molecular Genetics Laboratory Center of Cardiovascular Surgery and Transplantation Brno Czech Republic

Zobrazit více v PubMed

Wilkinson JC, Cepero E, Boise LH, Duckett CS. Upstream regulatory role for XIAP in receptor-mediated apoptosis. Mol. Cell. Biol. 2004;24:7003–7014. PubMed PMC

Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300–304. PubMed

Kenneth NS, Duckett CS. IAP proteins: regulators of cell migration and development. Curr. Opin. Cell Biol. 2012;24:871–875. PubMed

Galbán S, Duckett CS. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ. 2010;17:54–60. PubMed PMC

Bertrand MJM, et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity. 2009;30:789–801. PubMed

Wang C, et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001;412:346–351. PubMed

Hasegawa M, et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activation. EMBO J. 2008;27:373–383. PubMed PMC

Krieg A, et al. XIAP mediates NOD signaling via interaction with RIP2. Proc. Natl Acad. Sci. USA. 2009;106:14524–14529. PubMed PMC

Damgaard RB, et al. The ubiquitin ligase XIAP Recruits LUBAC for NOD2 Signaling in Inflammation and Innate Immunity. Mol. Cell. 2012;46:746–758. PubMed

Damgaard RB, et al. Disease‐causing mutations in the XIAP BIR 2 domain impair NOD 2‐dependent immune signalling. EMBO Mol. Med. 2013;5:1278–1295. PubMed PMC

Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn′s disease. Annu. Rev. Genomics Hum. Genet. 2009;10:89–116. PubMed

Zeissig Y, et al. XIAP variants in male Crohn′s disease. Gut. 2015;64:66–76. PubMed

Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin. Cell Dev. Biol. 2015;39:115–123. PubMed

Vallurupalli, M. & Berliner, N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood10.1182/blood.2019002289 (2019). PubMed PMC

Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br. J. Haematol. 2013;161:609–622. PubMed

Shim JO. Recent advance in very early onset inflammatory bowel disease. Pediatr. Gastroenterol. Hepatol. Nutr. 2019;22:41. PubMed PMC

Speckmann C, et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin. Immunol. 2013;149:133–141. PubMed

Nielsen OH, LaCasse EC. How genetic testing can lead to targeted management of XIAP deficiency–related inflammatory bowel disease. Genet. Med. 2017;19:133–143. PubMed

Xu T, et al. X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic. Eur. J. Pediatr. 2020;179:327–338. PubMed PMC

Y. T, et al. Gene therapy for X-linked inhibitor of apoptosis protein (XIAP) deficiency. Hum. Gene Ther. 2017;28:A31–A32.

Liu J, et al. X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. J. Biol. Chem. 2011;286:15630–15640. PubMed PMC

Quaranta M, et al. Consequences of identifying XIAP deficiency in an adult patient with inflammatory bowel disease. Gastroenterology. 2018;155:231–234. PubMed

Schmid JP, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency) Blood. 2011;117:1522–1529. PubMed

Yang X, et al. Clinical and genetic characteristics of XIAP deficiency in Japan. J. Clin. Immunol. 2012;32:411–420. PubMed

Marsh RA, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010;116:1079–1082. PubMed PMC

Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood. 2010;116:3398–3408. PubMed PMC

Rigaud S, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444:110–114. PubMed

Gentle IE, et al. Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. Blood. 2014;123:659–668. PubMed

Sabbah A, et al. Activation of innate immune antiviral responses by Nod2. Nat. Immunol. 2009;10:1073–1080. PubMed PMC

Kapoor A, Forman M, Arav-Boger R. Activation of nucleotide oligomerization domain 2 (NOD2) by human cytomegalovirus initiates innate immune responses and restricts virus replication. PLoS ONE. 2014;9:e92704. PubMed PMC

Ellison MA, Gearheart CM, Porter CC, Ambruso DR. IFN-γ alters the expression of diverse immunity related genes in a cell culture model designed to represent maturing neutrophils. PLoS ONE. 2017;12:e0185956. PubMed PMC

Zhan Y, Carrington EM, Zhang Y, Heinzel S, Lew AM. Life and death of activated T cells: how are they different from naïve T cells? Front. Immunol. 2017;8:1809. PubMed PMC

Hildeman D, Jorgensen T, Kappler J, Marrack P. Apoptosis and the homeostatic control of immune responses. Curr. Opin. Immunol. 2007;19:516–521. PubMed PMC

Mikhalkevich N, et al. Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation. J. Immunol. 2006;176:1553–1560. PubMed

Vince JE, et al. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity. 2012;36:215–227. PubMed

Yabal M, et al. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep. 2014;7:1796–1808. PubMed

Canna SW, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 2014;46:1140–1146. PubMed PMC

Romberg N, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 2014;46:1135–1139. PubMed PMC

Aguilar C, et al. Characterization of Crohn disease in X-linked inhibitor of apoptosis–deficient male patients and female symptomatic carriers. J. Allergy Clin. Immunol. 2014;134:1131–1141.e9. PubMed

Ammann S, et al. A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency. Clin. Exp. Immunol. 2014;176:394–400. PubMed PMC

Engel T, et al. Effectiveness and safety of Ustekinumab for Crohn′s disease; systematic review and pooled analysis of real-world evidence. Dig. Liver Dis. 2019;51:1232–1240. PubMed

Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–1760. PubMed PMC

Li H, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25:2078–2079. PubMed PMC

Koboldt DC, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012;22:568–576. PubMed PMC

Cingolani P, et al. Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift. Front. Genet. 2012;3:35. PubMed PMC

Parackova, Z. et al. Mutual alteration of NOD2-associated Blau syndrome and IFNγR1 deficiency. J. Clin. Immunol. 10.1007/s10875-019-00720-6 (2019). PubMed

Kanderova, V. et al. Lymphoproliferation, immunodeficiency and early-onset inflammatory bowel disease associated with a novel mutation in Caspase 8. Haematologica10.3324/haematol.2018.201673 (2018). PubMed PMC

Lašťovička J, Rataj M, Bartůňková J. Assessment of lymphocyte proliferation for diagnostic purpose: comparison of CFSE staining, Ki-67 expression and 3H-thymidine incorporation. Hum. Immunol. 2016;77:1215–1222. PubMed

Zentsova, I. et al. Monocytes contribute to DNA sensing through the TBK1 signaling pathway in type 1 diabetes patients. J. Autoimmun. 10.1016/j.jaut.2019.06.005 (2019). PubMed

Natural Course of Activated Phosphoinositide 3-Kinase Delta Syndrome in Childhood and Adolescence